Beactica Announces Drug Discovery Research Collaboration with GE Healthcare and Uppsala University
News Jan 16, 2009
Beactica has announced a new research collaboration agreement with GE Healthcare and Uppsala University (Sweden). The collaboration combines Beactica's approach to fragment-based drug discovery and GE Healthcare's Biacore™ technology with enzymology expertise from Uppsala University.
Under the terms of the agreement, the consortium will collaborate to develop the next generation of Biacore™ surface plasmon resonance instruments and applications for fragment-based drug discovery.
The project also aims to identify high-quality leads against a clincally important, undisclosed protein target from Beactica's discovery pipeline. Financial terms of the agreement were not disclosed.
"We look forward to deepening our relationship with GE Healthcare and Uppsala University," said Beactica's CEO, Dr Per Kallblad. "The Biacore technology is a core component of our kinetics-integrated lead discovery platform. Being an active part in the development of next - generation applications from GE Healthcare will enable us to stay at the forefront of our field."
Strong Immune Response in Diseased Corals Potential Trade-OffNews
Researchers have found a correlation between a strong immune response in diseased corals and a lower expression of genes associated with growth and reproduction.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE